NCT00002025View on ClinicalTrials.gov

Open Label Ganciclovir Therapy for Sight- or Life-Threatening Cytomegalovirus Disease in the Immunocompromised Patient

NACompletedINTERVENTIONAL
Timeline

Start Date

Not specified

Conditions
Cytomegalovirus InfectionsCytomegalovirus RetinitisHIV Infections
Interventions
DRUG

Ganciclovir

Trial Locations (1)

94303

Roche Global Development - Palo Alto, Palo Alto

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00002025 - Open Label Ganciclovir Therapy for Sight- or Life-Threatening Cytomegalovirus Disease in the Immunocompromised Patient | Biotech Hunter | Biotech Hunter